1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,620 | 2,740 | 09:00 | |
| 2,620 | 2,980 | 02.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Exicure: NASDAQ rügt verspätete Einreichung des Quartalsberichts | 1 | Investing.com Deutsch | ||
| EXICURE Aktie jetzt für 0€ handeln | |||||
| Mo | Exicure receives Nasdaq notice for delayed Q1 filing | 1 | Seeking Alpha | ||
| Mo | Exicure, Inc.: Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q | 44 | GlobeNewswire (Europe) | REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the "Company") announced today that it received a notification letter from the Listing Qualifications Department... ► Artikel lesen | |
| Mo | EXICURE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | EXICURE, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | EXICURE, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings | ||
| 23.04. | Exicure, Inc.: Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) | 83 | GlobeNewswire (Europe) | CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based... ► Artikel lesen | |
| 10.04. | EXICURE, INC. - 8-K, Current Report | - | SEC Filings | ||
| 02.04. | Exicure, Inc.: Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions | 197 | GlobeNewswire (Europe) | REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following... ► Artikel lesen | |
| 26.03. | Exicure GAAP EPS of -$0.79 | 1 | Seeking Alpha | ||
| 25.03. | EXICURE, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 25.03. | EXICURE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | Exicure, Inc. Reports Full Year 2025 Financial Results | 307 | GlobeNewswire (Europe) | REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the "Company") releases the following financial results for the year ended December 31, 2025. 2025 Financial Results... ► Artikel lesen | |
| 17.02. | EXICURE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.02. | EXICURE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Exicure, Inc.: Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant | 1 | GlobeNewswire (USA) | ||
| 22.01. | EXICURE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.01. | Exicure to present phase 2 burixafor data at 2026 transplantation meeting | 1 | Investing.com | ||
| 21.01. | Exicure, Inc.: Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings | 1 | GlobeNewswire (USA) | ||
| 09.12.25 | Exicure Shares Surge 41% On Promising Phase 2 Data For Multiple Myeloma Drug | 1 | RTTNews |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVARTIS | 123,88 | -0,35 % | DEUTSCHE BANK RESEARCH stuft NOVARTIS AG auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novartis anlässlich der Investorenveranstaltung "dbAccess European Champions Conference" mit einem Kursziel von 135 Franken... ► Artikel lesen | |
| GILEAD SCIENCES | 109,56 | -0,09 % | Während Merck, Amgen, Novo Nordisk und Fresenius Milliarden bewegen, wächst die Fantasie im Zelltherapie-Sektor | ||
| AURORA CANNABIS | 3,050 | +0,66 % | Aurora Deepens its Impact for Veterans Across Canada | ||
| CANOPY GROWTH | 0,915 | +0,97 % | Canopy Growth Corporation: Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition | Pablo's Revenge, Dante'z Inferno, and Frost'd Flakes launched under Tweed brand Up to five additional strains expected to follow in June 2026 Company targeting rapid growth in Germany's medical... ► Artikel lesen | |
| ELI LILLY | 914,90 | -0,05 % | Eli Lilly vor neuer Bewertungsrunde: Warum trotz Rekordkursen weiterer Aufwärtsspielraum bestehen könnte | Eli Lilly steht nach massiven Kursgewinnen weiter im Fokus institutioneller Investoren. Der Konzern gilt als einer der zentralen Profiteure im lukrativen Markt für Adipositas- und Diabetes-Therapien... ► Artikel lesen | |
| MERCK & CO | 100,02 | +0,58 % | Moderna, Inc.: Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting | At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence... ► Artikel lesen | |
| ASTRAZENECA | 152,10 | -0,30 % | Milliardenchance auf der Kippe: FDA bremst AstraZeneca bei wichtigem Brustkrebs-Medikament aus | © Foto: Ying Tang - picture alliance / NurPhotoDie US-Arzneimittelbehörde verschiebt ihre Entscheidung über AstraZenecas Brustkrebs-Pille Camizestrant. Neue Daten sollen Zweifel ausräumen.Die US-Arzneimittelbehörde... ► Artikel lesen | |
| TILRAY BRANDS | 4,650 | +0,22 % | Tilray Brands, Inc.: BrewDog verwandelt die diesjährige Fußball-WM in ein landesweites Sommerfest rund um Bier, Bars und große Spielmoment | BrewDog startet die Multichannel-Kampagne "Underdog" im Einzelhandel, in Bars und in digitalen Medien - einschließlich des landesweiten Gewinnspiels "Win a Year of Beer" und öffentlicher Public-Viewing-Events... ► Artikel lesen | |
| INNOCAN PHARMA | 2,060 | -2,37 % | Innocan Pharma Corporation: Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M | HERZLIYA, Israel and CALGARY, AB, May 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,302 | 0,00 % | PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Arzneiwerk... ► Artikel lesen | |
| CRONOS GROUP | 2,322 | -1,28 % | Cronos Group Inc.: Cronos Group Reports 2026 First Quarter Results | Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada1 Ninth consecutive quarter... ► Artikel lesen | |
| VIATRIS | 13,424 | -0,52 % | Dividendenbekanntmachungen (22.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,78 USD 0,6712 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0645 EUR ADVANCED ENERGY INDUSTRIES... ► Artikel lesen | |
| EYEPOINT | 10,700 | 0,00 % | EyePoint, Inc.: EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data | - LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after - - Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously... ► Artikel lesen | |
| BAUSCH HEALTH | 4,318 | +0,47 % | Bausch Health Companies Inc.: Bausch Health Announces 2026 Annual Meeting of Shareholder Results | LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,935 | -0,74 % | Organigram Global Inc.: Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram") and Sanity Group GmbH ("Sanity" or "Sanity Group") jointly announced the successful closing of Organigram's previously... ► Artikel lesen |
EXICURE INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXICURE INC finden Sie auf Wallstreet Online.